Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCULATE: ctDNA-Based Adjuvant Treatment in Stage II Colon Cancer
NCT04089631Phase 3Recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in colon cancer and rectal cancer (3 arms), sponsored by Technische Universität Dresden. Primary endpoint: Disease Free Survival at 60 months. Started Jun 2020; status: recruiting.
02
Drugs
capecitabine
03
Conditions
colon cancerrectal cancer
Beyond the preview
Go deeper on NCT04089631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089631.